Drugs Xagena
The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Rozlytrek ( Entrectinib ), a treatment for adult and adolescent patients whose cancers have the specific genetic defec ...
The European Commission has granted conditional marketing authorisation for Rozlytrek ( Entrectinib ) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours ex ...
